<DOC>
	<DOC>NCT00292461</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of zonisamide for anti-epilepsy drugs (AEDs) treated subjects with refractory simple partial, complex partial or partial with secondary generalized seizures.</brief_summary>
	<brief_title>A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Inclusion criteria: Subjects must sign and date the informed consent form Clinical diagnosis as refractory epilepsy Exclusion criteria: Progressive neurologic disease Serious psychiatric disease Hemolytic anemia G6PD (glucose6phosphate dehydrogenase) deficiency Acute intermittent porphyrias Subjects who have received study drugs (Zonisamide, Lamotrigine) in the past Drug or alcohol addiction Renal impairment (serum creatinine â‰§ 1.5 mg/dl), or hepatic abnormality (ALT or AST &gt; 2x ULN) StevensJohnson syndrome Progressive exfoliative dermatitis Pregnant, lactating or of childbearing potential female Regularly taking oral contraceptives Hypersensitivity to study drugs Severe cardiac disease (New York Heart Association Functional Class III and IV) History of malignancy within 5 years Taking valproic acid within 7 days prior to screening Subjects with simple partial seizures without motor component</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizures</keyword>
</DOC>